Comparison of incretin-related drugs (GLP-1 receptor agonists and DPP IV inhibitors) and insulin for clinical effects in patients with type 2 diabetes mellitus

Comparison of incretin-related drugs (GLP-1 receptor agonists and DPP IV inhibitors) and insulin for clinical effects in patients with type 2 diabetes mellitus - Comparison of incretin-related drugs (GLP-1 receptor agonists and DPP IV inhibitors) and insulin for clinical effects in patients with type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009690

Enrollment

120

Registered

2013-01-04

Start date

2011-06-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

liraglutide 0.6-0.9mg/day alogliptin 25mg/day glargine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c (JDS):7.0-11.0% Type 2 diabetes Patients with written informed consent

Exclusion criteria

Exclusion criteria: 1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)pregnacy 4)liver cirrhosis, chronic renal failure (serum creatinine level>2.0mg/dL), respiratory failure 5)allergy for liraglutide, alogliptin and glargine 6)patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
change of HbA1c and BW (body mass index)	—

Countries

Japan

Contacts

Public ContactKenta Okada

Jichi Medical University Endocrinology and Metabolism

kokada@jichi.ac.jp0285-44-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026